[Preliminary clinical trials of Agr 1240].
D000293:Adolescent; D000328:Adult; D000374:Aggression / Q000187:drug effects; D001007:Anxiety / Q000188:drug therapy; D003863:Depression / Q000188:drug therapy; D005021:Ethylamines / Q000008:administration & dosage; D005221:Fatigue / Q000188:drug therapy; D005260:Female; D006624:Hippocampus / Q000187:drug effects; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects; D007989:Libido / Q000187:drug effects; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage*; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy; D011379:Prognosis; D011602:Psychophysiologic Disorders / Q000188:drug therapy; D011618:Psychotic Disorders / Q000188:drug therapy; D011724:Pyridazines / Q000008:administration & dosage*
D005021:Ethylamines; D009025:Morpholines; D011724:Pyridazines
Premiers essais cliniques de l'Agr 1240.